Amyloidosis: Pathogenesis and new therapeutic options

Journal of Clinical Oncology

Volumn 29, Issue 14, 2011, Pages 1924-1933

  Merlini, Giampaolo ^a,b,c   Seldin, David C ^a,b,c   Gertz, Morie A ^a,b,c  

^a UNIVERSITY OF PAVIA   (Italy)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; COLCHICINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; TROPONIN I; TROPONIN T; VINCRISTINE;

ALGORITHM; AMYLOIDOSIS; BRADYCARDIA; CONSTIPATION; CYTOPENIA; DIAGNOSTIC ACCURACY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; EDEMA; FATIGUE; HEART AMYLOIDOSIS; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FOLDING; RASH; REVIEW; SEDATION; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AMYLOIDOSIS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; PROGNOSIS;

EID: 79955842001     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.2271     Document Type: Review

References (103)

1. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 349:583-596, 2003 (Pubitemid 36951371)
2. Dember LM, Hawkins PN, Hazenberg BP, et al: Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 356:2349-2360, 2007 (Pubitemid 46883769)
3. Sekijima Y, Kelly JW, Ikeda S: Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 14:3219-3230, 2008
4. Pepys MB, Herbert J, Hutchinson WL, et al: Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417:254-259, 2002 (Pubitemid 34534701)
5. Solomon A, Weiss DT, Wall JS: Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm 18:853-860, 2003 (Pubitemid 38064016)
6. Klyubin I, Walsh DM, Lemere CA, et al: Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11:556-561, 2005 (Pubitemid 40685979)
7. Bodin K, Ellmerich S, Kahan MC, et al: Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468:93-97, 2010
8. Sipe JD, Benson MD, Buxbaum JN, et al: Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 17:101-104, 2010
9. Kyle RA, Linos A, Beard CM, et al: Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79:1817-1822, 1992
10. Lachmann HJ, Booth DR, Booth SE, et al: Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 346:1786-1791, 2002 (Pubitemid 34586914)
11. Anesi E, Palladini G, Perfetti V, et al: Therapeutic advances demand accurate typing of amyloid deposits. Am J Med 111:243-244, 2001 (Pubitemid 32786958)
12. Comenzo RL, Zhou P, Fleisher M, et al: Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: Patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 107:3489-3491, 2006
13. Lambert MP, Barlow AK, Chromy BA, et al: Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95:6448-6453, 1998
14. Reixach N, Deechongkit S, Jiang X, et al: Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A 101:2817-2822, 2004 (Pubitemid 38327694)
15. Shi J, Guan J, Jiang B, et al: Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 107:4188-4193, 2010
16. Palladini G, Lavatelli F, Russo P, et al: Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854-3858, 2006 (Pubitemid 43726787)
17. Palladini G, Barassi A, Klersy C, et al: The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 116:3426-3430, 2010
18. Merlini G, Stone MJ: Dangerous small B-cell clones. Blood 108:2520-2530, 2006
19. Palladini G, Russo P, Bosoni T, et al: Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 55:499-504, 2009
20. Dispenzieri A, Kyle R, Merlini G, et al: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:215-224, 2009
21. Comenzo RL, Wally J, Kica G, et al: Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: Association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br J Haematol 106: 744-751, 1999 (Pubitemid 29434217)
22. Perfetti V, Casarini S, Palladini G, et al: Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloidassociated germline gene segment. Blood 100:948-953, 2002 (Pubitemid 34832622)
23. Prokaeva T, Spencer B, Kaut M, et al: Soft tissue, joint, and bone manifestations of AL amyloidosis: Clinical presentation, molecular features, and survival. Arthritis Rheum 56:3858-3868, 2007 (Pubitemid 350100719)
24. Comenzo RL, Hoffman JE, Hassoun H, et al: Pathobiologic associations of plasma cell (PC) overexpression of Cyclin D1 (CCND1) in systemic AL amyloidosis (AL). Amyloid 17:61, 2010 (suppl 1; abstr OP-044)
25. Zhou P, Comenzo RL, Olshen AB, et al: CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 111:3403-3406, 2008
26. Deshmukh M, Elderfield K, Rahemtulla A, et al: Immunophenotype of neoplastic plasma cells in AL amyloidosis. J Clin Pathol 62:724-730, 2009
27. Swan N, Skinner M, O'Hara CJ: Bone marrow core biopsy specimens in AL (primary) amyloidosis: A morphologic and immunohistochemical study of 100 cases. Am J Clin Pathol 120:610-616, 2003
28. van Gameren II, Hazenberg BP, Bijzet J, et al: Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 54:2015-2021, 2006
29. Biewend ML, Menke DM, Calamia KT: The spectrum of localized amyloidosis: A case series of 20 patients and review of the literature. Amyloid 13:135-142, 2006 (Pubitemid 44630056)
30. Hawkins PN, Myers MJ, Lavender JP, et al: Diagnostic radionuclide imaging of amyloid: Biological targeting by circulating human serum amyloid P component. Lancet 1:1413-1418, 1988
31. Arbustini E, Morbini P, Verga L, et al: Light and electron microscopy immunohistochemical characterization of amyloid deposits. Amyloid 4:157-170, 1997 (Pubitemid 127496648)
32. Lavatelli F, Perlman DH, Spencer B, et al: Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 7:1570-1583, 2008
33. Vrana JA, Gamez JD, Madden BJ, et al: Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114:4957-4959, 2009
34. Falk RH: Diagnosis and management of the cardiac amyloidoses. Circulation 112:2047-2060, 2005
35. Bellavia D, Pellikka PA, Al-Zahrani GB, et al: Independent predictors of survival in primary systemic (AL) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: An observational cohort study. J Am Soc Echocardiogr 23:643-652, 2010
36. Koyama J, Falk RH: Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 3:333-342, 2010
37. Maceira AM, Joshi J, Prasad SK, et al: Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111:186-193, 2005 (Pubitemid 40139730)
38. Palladini G, Campana C, Klersy C, et al: Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107:2440-2445, 2003 (Pubitemid 36605226)
39. Dispenzieri A, Kyle RA, Gertz MA, et al: Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361:1787-1789, 2003 (Pubitemid 36638428)
40. Dispenzieri A, Gertz MA, Kyle RA, et al: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 22:3751-3757, 2004 (Pubitemid 41095215)
41. Dietrich S, Schönland SO, Benner A, et al: Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 116:522-528, 2010
42. Kastritis E, Wechalekar AD, Dimopoulos MA, et al: Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 28:1031-1037, 2010
43. Dispenzieri A, Gertz MA, Kyle RA, et al: Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104:1881-1887, 2004
44. Dispenzieri A, Lacy MQ, Katzmann JA, et al: Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 107:3378-3383, 2006
45. Wechalekar AD, Wassef NL, Gibbs SD, et al: A new staging system for AL amyloidosis incorporating serum free light chains, cardiac troponin-T and NT-ProBNP. Blood (ASH Annual Meeting Abstracts) 114, 2009 (abstr 2796)
46. Kumar S, Dispenzieri A, Lacy MQ, et al: A novel prognostic staging system for light chain amyloidosis (AL) incorporating markers of plasma cell burden and organ involvement. Blood (ASH Annual Meeting Abstracts) 114, 2009 (abstr 2797)
47. Gertz MA, Comenzo R, Falk RH, et al: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79:319-328, 2005
48. Gertz M, Merlini G: Definition of organ involvement and response to treatment in AL amyloidosis: An updated consensus opinion. Amyloid 17:48-49, 2010 (suppl 1; abstr CP-B)
49. Gertz MA, Lacy MQ, Dispenzieri A, et al: Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: Importance of achieving a complete response. Haematologica 92:1415-1418, 2007 (Pubitemid 350144161)
50. Lachmann HJ, Gallimore R, Gillmore JD, et al: Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122:78-84, 2003 (Pubitemid 36819341)
51. Sanchorawala V, Seldin DC, Magnani B, et al: Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 36:597-600, 2005 (Pubitemid 43115014)
52. Wechalekar AD, Merlini G, Gillmore JD, et al: N-terminal fragment of brain natriuretic peptide (NT-ProBNP): A new response criterion in AL amyloidosis. Amyloid 17:84-85, 2010 (suppl 1; abstr OP-081)
53. Skinner M, Anderson J, Simms R, et al: Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 100: 290-298, 1996 (Pubitemid 26111626)
54. Kyle RA, Gertz MA, Greipp PR, et al: A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336:1202-1207, 1997 (Pubitemid 27183649)
55. Palladini G, Anesi E, Perfetti V, et al: A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 113:1044-1046, 2001 (Pubitemid 32634774)
56. Gertz MA, Lacy MQ, Lust JA, et al: Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol 16:104-109, 1999 (Pubitemid 29349856)
57. Gertz MA, Lacy MQ, Lust JA, et al: Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. Am J Hematol 61:115-119, 1999 (Pubitemid 29252388)
58. Dhodapkar MV, Hussein MA, Rasmussen E, et al: Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: Results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 104:3520-3526, 2004
59. Skinner M, Sanchorawala V, Seldin DC, et al: High-dose melphalan and autologous stemcell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 140:85-93, 2004
60. Gertz MA, Lacy MQ, Dispenzieri A, et al: Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 34:1025-1031, 2004 (Pubitemid 40028833)
61. Palladini G, Perfetti V, Obici L, et al: Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103:2936-2938, 2004 (Pubitemid 38451663)
62. Jaccard A, Moreau P, Leblond V, et al: High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357:1083-1093, 2007 (Pubitemid 47443213)
63. Palladini G, Perfetti V, Perlini S, et al: The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105:2949-2951, 2005 (Pubitemid 40446290)
64. Wechalekar AD, Goodman HJ, Lachmann HJ, et al: Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109:457-464, 2007 (Pubitemid 46105938)
65. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109:465-470, 2007 (Pubitemid 46105939)
66. Sanchorawala V, Wright DG, Rosenzweig M, et al: Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood 109:492-496, 2007 (Pubitemid 46105943)
67. Reece DE, Hegenbart U, Sanchorawala V, et al: Weekly and twice-weekly bortezomib in AL amyloidosis: Results of a phase II study. J Clin Oncol 28:578s, 2010 (suppl; abstr 8023)
68. Dispenzieri A, Gertz MA, Hayman SR, et al: A phase II study of pomalidomide and dexamethasone in previously treated light-chain (AL) amyloidosis. J Clin Oncol 28:579s, 2010 (suppl; abstr 8025)
69. Wardley AM, Jayson GC, Goldsmith DJ, et al: The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer 78:774-776, 1998 (Pubitemid 28418312)
70. Gertz MA, Lacy MQ, Lust JA, et al: Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 17:262-267, 1999 (Pubitemid 29022401)
71. Palladini G, Russo P, Nuvolone M, et al: Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 110:787-788, 2007 (Pubitemid 47105419)
72. Palladini G, Foli A, Milani P, et al: Oral melphalan and dexamethasone for AL amyloidosis: Efficacy, prognostic factors and response criteria. Amyloid 17:81-82, 2010 (suppl 1; abstr OP-076)
73. Lebovic D, Hoffman J, Levine BM, et al: Predictors of survival in patients with systemic lightchain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 143:369-373, 2008
74. Moreau P, Leblond V, Bourquelot P, et al: Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients. Br J Haematol 101:766-769, 1998 (Pubitemid 28308529)
75. Saba N, Sutton D, Ross H, et al: High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 24:853-855, 1999 (Pubitemid 29500345)
76. Comenzo RL, Vosburgh E, Falk RH, et al: Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 91:3662-3670, 1998 (Pubitemid 28225733)
77. Perfetti V, Siena S, Palladini G, et al: Longterm results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica 91:1635-1643, 2006 (Pubitemid 46032961)
78. Cohen AD, Zhou P, Chou J, et al: Riskadapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: Results of a phase II trial. Br J Haematol 139:224-233, 2007 (Pubitemid 47495869)
79. Seldin DC, Anderson JJ, Skinner M, et al: Successful treatment of AL amyloidosis with highdose melphalan and autologous stem cell transplantation in patients over age 65. Blood 108:3945-3947, 2006 (Pubitemid 44864581)
80. Sanchorawala V, Skinner M, Quillen K, et al: Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 110:3561-3563, 2007 (Pubitemid 350159622)
81. Dember LM, Sanchorawala V, Seldin DC, et al: Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med 134:746-753, 2001 (Pubitemid 32402067)
82. Leung N, Dispenzieri A, Fervenza FC, et al: Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis 46:270-277, 2005 (Pubitemid 41040355)
83. Seldin DC, Anderson JJ, Sanchorawala V, et al: Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 104: 1888-1893, 2004
84. Seldin DC, Choufani EB, Dember LM, et al: Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 3:241-246, 2003 (Pubitemid 36416849)
85. Palladini G, Russo P, Lavatelli F, et al: Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 88:347-350, 2009
86. Moreau P, Jaccard A, Benboubker L, et al: Lenalidomide in combination with melphalan and dexamethasone in patients with newly-diagnosed light-chain (AL)-amyloidosis: A multicenter phase I/II dose escalation study. Blood 116:4777-4782, 2010
87. Kumar S, Hayman SR, Buadi F, et al: A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis. Blood (ASH Annual Meeting Abstracts) 114, 2009 (abstr 3853)
88. Kastritis E, Roussou M, Migkou M, et al: A phase I/II study of lenalidomide (R) with low-dose dexamethasone (d) and cyclophosphamide (C) for patients with primary systemic (AL) amyloidosis. Blood (ASH Annual Meeting Abstracts) 114, 2009 (abstr 428)
89. Palladini G, Russo P, Zenone-Bragotti L, et al: A phase II trial of cyclophosphamide, lenalidomide, and dexamethasone (CLD) in previously treated patients with AL amyloidosis. Blood (ASH Annual Meeting Abstracts) 114, 2009 (abstr 2863)
90. Sitia R, Palladini G, Merlini G: Bortezomib in the treatment of AL amyloidosis: Targeted therapy? Haematologica 92:1302-1307, 2007
91. Oliva L, Pengo N, Palladini G, et al: Proteasome activity and stress in light chain amyloidosis. Amyloid 17:99, 2010 (suppl 1; abstr P-019)
92. Kastritis E, Anagnostopoulos A, Roussou M, et al: Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 92:1351-1358, 2007 (Pubitemid 350144152)
93. Wechalekar AD, Lachmann HJ, Offer M, et al: Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 93:295-298, 2008 (Pubitemid 351397721)
94. Reece DE, Sanchorawala V, Hegenbart U, et al: Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: Results of a phase 1 dose-escalation study. Blood 114:1489-1497, 2009
95. Landau H, Hassoun H, Cohen AD, et al: Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic light-chain amyloidosis (AL): A phase II study. Blood (ASH Annual Meeting Abstracts) 114, 2009 (abstr 533)
96. Gasparetto C, Sanchorawala V, Snyder RM, et al: Use of melphalan (M)/dexamethasone (D)/ bortezomib in AL amyloidosis. J Clin Oncol 28:579s, 2010 (suppl; abstr 8024)
97. Jimenez-Zepeda VH, Reeder CB, Mikhael JR, et al: Cyclophosphamide, bortezomib and dexamethasone (CyBORD) induces rapid and complete responses in patients with amyloidosis not eligible for peripheral blood stem cell transplant- .Blood (ASH Annual Meeting Abstracts) 114, 2009 (abstr 1857)
98. Specter R, Sanchorawala V, Seldin DC, et al: Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant [epub ahead of print on August 5, 2010]
99. Soni A, LeLorier P: Sudden death in nondilated cardiomyopathies: Pathophysiology and prevention. Curr Heart Fail Rep 2:118-123, 2005
100. Kristen AV, Dengler TJ, Hegenbart U, et al: Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 5:235-240, 2008
101. Gillmore JD, Goodman HJ, Lachmann HJ, et al: Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 107: 1227-1229, 2006 (Pubitemid 43156329)
102. Lacy MQ, Dispenzieri A, Hayman SR, et al: Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. J Heart Lung Transplant 27:823-829, 2008
103. Leung N, Griffin MD, Dispenzieri A, et al: Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant 5:1660-1670, 2005 (Pubitemid 40910448)